Refractory Acute Promyelocytic Leukemia (DBCOND0032868)
Identifiers
- Synonyms
- Not Available
Associated Data
- Indicated Drugs and Targets
Drug Description Targets Arsenic trioxide A chemotherapeutic agent used in the treatment of refractory or relapsed acute promyelocytic leukemia in patients with prior retinoid and anthracycline chemotherapy.- Inhibitor of nuclear factor kappa-B kinase subunit betatarget
- Transcription factor Juntarget
- G1/S-specific cyclin-D1target
- Mitogen-activated protein kinase 3target
- Mitogen-activated protein kinase 1target
- RAC-alpha serine/threonine-protein kinasetarget
- ATP-binding cassette sub-family C member 2transporter
- Thioredoxin reductase 1, cytoplasmictarget
- ATP-dependent translocase ABCB1transporter
- Cytochrome P450 3A4enzyme
- Cyclin-dependent kinase inhibitor 1target
- Histone deacetylase 1target
- Protein PMLtarget
- Albumincarrier
- Clinical Trials
Identifier Title Drug(s) Purpose Phase Status NCT00196768 Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic treatment 4 unknown_status